Introduction
Hematological malignancies account for approximately 9% of all newly diagnosed cancers in the United States. 1 Changes in hematopoiesis also occur in many medical conditions and significantly contribute to morbidity and mortality. Although blood disorders arise primarily from defects in hematopoietic cells, contextual signals from stromal cells in the bone marrow (BM) microenvironment or "niche" may also influence disease development. Notch ligands, Cxcl12, and angiopoietin-1 (Angpt1). 3, 4 Although early mouse studies have implicated mature osteoblasts as important regulators of HSC numbers, [5] [6] [7] more recent work has shown that immature OBCs and perivascular MSCs are in fact the major BM niche constituents ensuring HSC maintenance. [8] [9] [10] Co-culture experiments have also demonstrated the functional importance of interactions with ECs and OBCs in regulating blood production by HSCs. [11] [12] These findings indicate that ECs, OBCs, and MSCs are three essential BM stromal cell populations that regulate HSC activity and blood homeostasis.
Recent work has also illustrated how changes in BM stromal cells contribute to the development of hematological diseases. Genetic ablation of the retinoblastoma, 13 retinoic acid receptor gamma, 14 or miRNA processing enzyme Dicer 15 genes in BM stromal cells or osteoprogenitor cells all resulted in dysfunctional BM niches promoting myeloproliferative neoplasms or myelodysplastic syndromes. Furthermore, the loss of G s G-protein-coupled receptor (GPCR) signaling in osteoprogenitor cells was found to impair B-cell development. 16 For personal use only. on . by guest www.bloodjournal.org From 
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These examples stress the role of BM stromal niche cells in regulating hematopoiesis, and indicate that appropriate GPCR signals are crucial for normal blood development.
Surprisingly little is known about how abnormal G s -GPCR signaling in osteoblastic cells affects hematopoiesis. Activation of the key osteoblast G s GPCR parathyroid hormone receptor 1 (PTHR1) by parathyroid hormone (PTH) causes changes in osteoblast proliferation, differentiation, and function. 17 Clinically, daily injection of recombinant PTH is used to increase bone formation for osteoporosis treatment. 18 Recently, PTH injections were also shown to increase both HSC mobilization and engraftment in mouse models of BM transplantation. 5, 19, 20 These studies have led to clinical trials using PTH to enhance HSC-based therapies 21 and raised the exciting possibility of improving HSC function by modulating osteoblast factors,
particularly via GPCR signals.
The complexity of the G s α gene locus, embryonic lethality of G s α over-activity, and genetic imprinting of this locus pose significant challenges for manipulating G s signaling in vivo. 22 Engineered receptors such as RASSLs (receptors activated solely by synthetic ligands)
are powerful tools for studying GPCR signaling. 23 RASSLs no longer respond to endogenous hormones but can be activated by synthetic small-molecule ligands. RASSLs are also small genes easily expressed in constructs and transgenes. We previously showed that the RASSL Rs1 (engineered from the 5HT4 serotonin receptor) had strong basal G s signaling activity even in the absence of its ligand. 24 Bone analyses. Bone densitometry (DXA) was performed as described. 25 Mid-femur CT scans (50 slices) were performed on a vivaCT40 MicroCT (Scanco; 55 kV x-ray energy, 10.5 µm voxels, 1000 ms integration times). Femur tissue volume (TV), mineralized bone volume (BV), and non-bone volume (TV-BV, Figure S1 ) were determined using segmentation values of 0.7/1/250, 25 corresponding to 400 mg hydroxyapatite/cm 3 , which includes mineralized bone and osteoid. Bones for hematoxylin and eosin staining were decalcified for 12-48 hours in 10%
EDTA/PBS before paraffin embedding, sectioning, and staining.
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Stromal and hematopoietic cell isolation. Hematopoietic and endosteal BM cells were purified from 12 bones (femurs, tibias, fibulas, humeri, ulnas, radii, and pelvis). Rs1 bones were precrushed by 3 blows of a 0.45 kg hammer then treated similarly to control bones. After crushing with mortar and pestle, bone chips were washed once in Hank's buffered saline solution (HBSS)/2% heat-inactivated fetal bovine serum (FBS) to release the loosely-adherent BM cells, and several times in HBSS without FBS until the chips were white. These washes were pooled and treated with ACK (150 mM NH 4 Cl, 10 mM KHCO 3 ) to lyse red blood cells (RBC). Residual bone material and dead cells were removed by Ficoll gradient (Histopaque-1119; Sigma). This hematopoietic BM fraction was not collagenase treated and was used in all subsequent hematopoietic analyses. Endosteal stromal cells were released from the hematopoietic-depleted bone chips by digestion with 3 mg/ml type I collagenase (Worthington) and 15 µg/ml DNAse dissolved in HBSS for 1 hour at 37ºC at 110 rpm, followed by Ficoll gradient. This stromal fraction was used in all subsequent analyses of endosteal populations. Since CD45 + hematopoietic cells still remain in this fraction, we calculated and applied a corrective efficiency ratio for BM cell isolation ( Figure S2 ). Splenocytes were obtained by mechanical dissociation followed by ACK treatment. RBC lysis was not performed when analyzing erythrocyte precursors. Tail vein peripheral blood was collected into K 2 EDTA-coated collection tubes (Becton Dickinson) for complete blood counts (CBC) or into ACK/10 mM EDTA buffer for flow cytometry. ELISAs were performed according to manufacturers' instructions (mouse Tpo and Epo, R&D Biosystems; mouse iPTH, Immutopics International). Cellularities were measured using a Vi-Cell automated cell counter (Beckman-Coulter) and CBCs were performed on a Hemavet950 analyzer (DREW Scientific).
Flow cytometry. Cell sorting and analysis for hematopoietic [28] [29] [30] and stromal 31, 32 BM populations were performed as described in Quantitative RT-PCR. RNA isolated from 600-23,000 purified cells using the Arcterus PicoPure RNA kit was amplified using the Nugen Pico WTA kit and cleaned using the Qiagen QiaQuick PCR purification kit following manufacturers' protocols. Quantitative RT-PCR on 10ng of amplified cDNA was performed on an ABI 7900HT thermocycler using Taqman probesets (Applied BioSystems; Table S2 ). Relative expression was calculated using the
Δ Δ
CT method normalized to GAPDH levels for each individual sample measured in triplicate.
Transplantations. Congenic recipients were lethally irradiated at 900 rad for FVB/N mice and 1100 rad for C57BL/6 mice delivered in split doses 3 hours apart. Cells were injected into the retro-orbital plexus of the recipients immediately after irradiation, and mice were treated with antibiotics for 6 weeks post-transplantation.
Cell culture. Colony-forming unit (CFU) activity was determined in IMDM-based methylcellulose medium (M3231; Stem Cell Technologies) supplemented with SCF, Flt3-L, IL-11, Tpo (25 ng/ml each), IL-3 (10 ng/ml), Epo (4 U/ml), and GM-CSF (20 ng/ml) (Peprotech). Colonies were counted after 7 days of culture. Co-culture experiments were performed in a 1:1 mix of Dulbecco's modified Eagle medium (DMEM) and α -modified Eagle medium (αMEM) containing 10% FBS, 1x penicillin/streptomycin and 50 mM 2-mercaptoethanol (co-culture medium). Sorted OBCs (2,000 cells per well) were cultured for 1 day in a 96-well plate. Non-adherent cells were washed once and naïve HSCs were sorted directly onto the adherent OBCs and grown in coculture medium supplemented with SCF, Flt3-L, and IL11 (25 ng/ml each). After 4 days, all cells 
Results

BM aplasia in mice with increased osteoblastic G s signaling
Rs1 mice progressively develop a dramatic bone phenotype characterized by increased trabecular bone formation, dense fibro-cellular infiltrates, and decreased hematopoietic cells within the putative BM space ( Figures 1A-F) . 25 Previous analysis by von Kossa/tetrachrome staining and synchrotron radiation imaging revealed under-mineralization and disorganized structure in Rs1 bones. 25, 33 MicroCT analyses at femoral mid-diaphyses detecting both bone and osteoid showed increased tissue volume (TV), mineralized bone volume (BV), and BV/TV fraction in 15-week-old (15 wk) Rs1 mice, but no decrease in non-bone volume (TV-BV)
(Figures 1G and S1). These results suggest that the total potential space for cellular BM components at the mid-diaphysis is not reduced in Rs1 mice despite massive changes in overall bone architecture. However, the absolute numbers of hematopoietic BM cells released by extensive washing from the crushed bones of 6-week-old (6 wk) and 12-week-old (12 wk) Rs1 mice were significantly reduced compared to control bones ( Figure 1H ). Although BM cell isolation was less efficient in Rs1 bones, 12 wk Rs1 mice still displayed 73% fewer hematopoietic BM cells than control mice when corrected for this difference in extraction efficiency ( Figure S2 ). Flow cytometric analysis of cells released from collagenase-treated bone chips revealed a 4-fold increase in the number of endosteal BM Lin -/CD45 -stromal cells in 12 wk Rs1 mice ( Figure 1I ). This finding indicates that stromal components infiltrate into the nonbone space in Rs1 mice. Thus, although Rs1 mice may have more potential space for BM components, the expanded stromal components and the increased non-mineralized matrix deposited by these cells reduce the capacity for hematopoietic cells, inducing BM aplasia.
Impaired BM megakaryopoiesis and erythropoiesis
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No compensatory extramedullary hematopoiesis
We then asked whether Rs1 mice developed extramedullary hematopoiesis to compensate for the BM aplasia and loss of megakaryocyte/erythrocyte progenitors. Both control and Rs1 spleens appeared similar in size and cellularity ( Figures S4A and S4B) , and neither kidneys nor livers of Rs1 mice showed histological evidence of extramedullary hematopoiesis (data not shown). Although 6 wk Rs1 spleens had mildly decreased T cell numbers, this resolved in 12 wk showed normal RBC counts and no sign of peripheral anemia or thrombocytopenia ( Figure   S4G ). Thus, despite severe developmental defects in megakaryocyte and erythrocyte lineages in the BM, no compensatory extramedullary hematopoiesis or altered levels of circulating blood cells was observed at steady state in Rs1 mice.
Defective RBC and platelet recovery after acute hematopoietic injury
To determine whether the BM defects compromised the ability of Rs1 mice to respond to hematopoietic injury, we challenged 9-week-old mice with a single dose of 5-fluorouracil (5-FU), a myelosuppressive agent that kills cycling hematopoietic cells ( Figure 3A ). While similar decline and recovery were observed in lymphoid and myeloid cells, Rs1 mice showed more rapid declines and incomplete recovery of RBC counts as compared to control mice. Platelet recovery was also significantly attenuated in Rs1 mice. We then injected mice weekly with escalating doses of 5-FU to model repeated hematopoietic injury, but observed no major differences in the survival rates of Rs1 and control mice ( Figure 3B ). These results illustrate the resilience of the blood system in Rs1 mice, and indicate that the BM megakaryocyte/erythrocyte defects contribute to impaired RBC and platelet recovery following acute hematopoietic injury.
Specific decrease in phenotypic and functional HSCs
We investigated whether the immature stem and progenitor BM compartments were affected in and 5B). We then profiled these endosteal stromal populations in 12 wk mice and found a dramatic increase in the number of OBCs, ECs, and MSCs in Rs1 bones ( Figure 5C ). These results indicate that the HSC loss observed in Rs1 mice is accompanied by a paradoxical expansion of stromal BM niche cells with putative HSC supportive activity, including Rs1-expressing OBCs.
We then performed qRT-PCR analyses on OBCs isolated from 12 wk control and Rs1 mice ( Figure 5D ). While Rs1 OBCs showed higher expression of the MSC marker Nestin, the osteoblast/chrondrocyte transcription factor Runx2, and the early osteoblast progenitor transcription factor Osterix (Osx), no changes were observed in the expression of mature osteoblast markers, including Collagen 1α1 (ColIα1), Osteopontin (Opn), and Osteocalcin (OC).
These molecular data confirm previous observations that expression of Rs1 in osteoblastic cells enriches for OBCs with an immature phenotype. 25, 33 However, no difference in maturity status was detected when control and Rs1 OBCs were compared in in vitro functional assays for CFUfibroblasts (CFU-F), CFU-alkaline phosphatase (CFU-Alk), and CFU-osteoblasts (CFU-OB) ( Figure 5E ). In addition, no difference in differentiation potential was observed between control and Rs1 MSCs ( Figure 5F ). These results indicate that Rs1-mediated G s signaling considerably increases the numbers of OBCs without affecting their overall differentiation properties.
For
Decreased HSC-supportive activity
Due to the early morbidity/mortality of Rs1 mice, we were unable to directly assess their BM niche properties by transplanting wild type HSCs into Rs1 hosts. Instead, we investigated the HSC-supportive ability of purified Rs1-expressing OBCs. Quantitative RT-PCR analyses of OBCs isolated from 12 wk mice revealed a striking decrease in the expression of HSC maintenance genes, including Cxcl12, Angpt1, and Vcam1, in Rs1 OBCs ( Figure 6A ). In contrast, expression of the pan-hematopoietic cytokine Scf and myeloid differentiation cytokine Il-6 were unchanged, consistent with the overall normal myeloid differentiation observed in Rs1 mice. We then performed short-term co-culture experiments where naive WT HSCs were grown for 4 days with or without OBCs isolated from 12 wk control or Rs1 mice, then assessed for hematopoietic production, CFU activity, and HSC function in transplantation experiments ( Figure 6B ). As expected, HSCs co-cultured with OBCs showed more hematopoietic differentiation and higher CFU potential than HSCs cultured without OBCs, and co-culture with Rs1 OBCs did not change these differentiation properties ( Figures 6C and 6D) . We then OBCs ( Figure S5D ). Thus, despite having similar abilities to promote HSC differentiation, Rs1
OBCs are impaired in their ability to maintain HSCs likely due to their decreased expression of HSC-supportive factors.
Discussion
Elucidating the complex interplay between BM hematopoietic and stromal compartments is crucial for understanding normal blood development and identifying new treatments for hematological diseases. Since OBCs are essential components of the BM HSC niche, we initially hypothesized that increased G s signaling in OBCs, and the associated increase in OBCs and bone mass, may improve the hematopoietic environment by promoting HSC maintenance and function. Instead, we found that Rs1-induced G s signaling in OBCs had unexpected adverse consequences for blood production, with lineage-specific defects in erythrocyte and platelet production that were aggravated upon hematopoietic injury. We also uncovered that continuous G s signaling resulted in an accumulation of OBCs with decreased expression of key HSC-supportive factors leading to compromised HSC maintenance in the BM (Figure 7 ).
At first, our findings appeared to contradict a prior study where a constitutively-active PTHR1 receptor (caPTHR1) expressed from the same ColI(2.3) promoter expanded both osteoblast and HSC numbers. 5 However, significant differences in methodologies and bone phenotype severity likely account for this discrepancy. While these approaches were state-of-the art techniques at that time, they unfortunately did not exclude non-self-renewing short-term HSCs and MPPs (contained in the LSK compartment) as contributors to the increased blood donor chimerism. In fact, we also observed increased LSK cells in young (6 wk) Rs1 mice although we did not find increased chimerism upon transplantation using CD45. This decreased HSC-supportive ability likely results from the compromised expression by Rs1
OBCs of key HSC-supportive factors, including Cxcl12, Angpt1, and Vcam1, and contributes to the HSC depletion occurring over time in Rs1 mice. Loss of quiescence and increased proliferation can also lead to HSC exhaustion; 38 however, the limited and transient changes in HSC cell cycle distribution we observed in Rs1 mice make this an unlikely explanation.
Furthermore, we found that the HSCs remaining in the BM niche of Rs1 mice are not functionally altered as measured in transplantation experiments. This may account for the surprising resilience of blood production in Rs1 mice despite severe HSC depletion and BM aplasia. Our results demonstrate that constitutive G s activation in OBCs renders the BM microenvironment refractory to HSC maintenance without compromising HSC self-renewal.
We also found that Rs1-mediated G s signaling in OBCs impaired BM erythropoiesis and megakaryopoiesis particularly after hematopoietic stress. However, Rs1 mice displayed normal erythropoiesis and megakaryopoiesis in the spleen and showed no overt signs of anemia or thrombocytopenia. It is therefore likely that the spleen, rather than the BM, produces the majority of circulating RBCs and platelets at steady state, while the BM defects only contribute to the delayed recovery observed after hematopoietic injury. These BM defects might result from erythroid/megakaryocyte progenitors being produced in lesser amounts than myeloid and
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From lymphoid progenitors by the HSCs remaining in Rs1 BM, or because they die upon differentiation due to poor support by the Rs1 BM microenvironment. Unfortunately, we could not detect Thrombopoietin (Tpo) or Erythropoietin (Epo) mRNA expression by qRT-PCR in our isolated control or Rs1 OBCs (data not shown), hence limiting our ability to determine if local production of these factors contributes to the observed BM defects. However, ELISA measurements on sera showed that while Epo was unaffected, the level of circulating Tpo was significantly reduced in Rs1 mice ( Figure S6 ). Although the mechanism leading to decreased Tpo production is unclear, it suggests that the hematopoietic defects in Rs1 mice may be influenced by systemic changes. We also observed a trend towards increased PTH levels in Rs1 serum ( Figure S6 ), suggesting that secretion of endogenous hormones may also be indirectly affected. Together, these results indicate that continuous G s activation in OBCs can induce broad systemic changes in key factors affecting the bone/hematopoietic axis and could contribute to lineage-specific defects in blood cell production. and pre-B cell precursors, reduced levels of mature B cells in the BM and periphery, and attenuated production of IL-7. 16 Our results indicate that the opposite (i.e., Rs1-mediated increased G s signaling in osteoblastic cells) neither affects B lymphopoiesis nor changes Il-7 expression (data not shown), but causes megakaryocyte and erythrocyte lineage defects that are exacerbated upon hematopoietic injury. Several observations suggest that similar regulation might occur in humans. Patients with increased serum PTH levels, as in primary hyperparathyroidism, develop increased BM fibrosis, cortical bone loss, and maintained trabecular bone formation 39 yet generally show no anemia except in rare cases of severe disease. 40 Additionally, patients with fibrous dysplasia, who have bone lesions resembling the Data are averages ± SD; *p≤0.05, **p≤0.01, ***p ≤ 0.001. 
